An earlier study reported that a common polymorphism in the 5 0 untranslated region of the epidermal growth factor (EGF) gene is associated with increased risk for cutaneous malignant melanoma (MM) and Breslow thickness. Since then, several independent studies have reported conflicting results that have challenged this hypothesis. However, none of the previous studies examined survival as the primary outcome. We therefore sought to study the association between this polymorphism and survival. One hundred and thirty patients diagnosed with MM with a Breslow thickness of 41.5 mm were included in this study. In our collective, the G/G genotype represented a significant risk factor for both shorter disease-free period (hazard ratio of 2.246, 95% CI: 1.06-4.78, P ¼ 0.036) and overall MM-specific survival (hazard ratio of 3.8, 95% CI: 1.5-9.5, P ¼ 0.004) compared with the A/A genotype, while the heterozygous A/G genotype showed an intermediate risk. In the present study, we demonstrate for the first time that the EGF A61G polymorphism is associated with survival. Our data suggest that this polymorphism is a potential marker for disease severity that predicts earlier progression of MM.
INTRODUCTION
After excision of the primary tumor, the occurrence of lymph node metastasis is the first clinically discernable sign of progressive disease in the majority of malignant melanoma (MM) cases (Balch et al., 2003) . MM with systemic involvement is effectively incurable due to its aggressive growth and resistance to apoptosis (Roka et al., 2005) . Tumor thickness, according to Breslow, is still the primary prognostic factor at initial diagnosis (Balch et al., 2001) . Relatively little is known about the molecular factors that mediate growth and survival of MM in vitro and in vivo, although recently an increasing body of evidence has emerged supporting the mitogen-activated protein kinase pathway as being involved in the oncogenic growth of this tumor (Bardeesy et al., 2005) . Mutational and functional analysis support the idea that epidermal growth factor (EGF), encoded by a single gene at locus 4q25-27, operates through this pathway via RAS and BRAF in melanocytic tumors (Mattei et al., 1994) .
A recent study showed that a single nucleotide polymorphism (SNP) located in the 5 0 untranslated region at position 61 influences the expression level of EGF in peripheral blood mononuclear cells (Shahbazi et al., 2002) . Moreover, Shahbazi et al. demonstrated not only a significant association between homozygosity for the EGF 61*G allele and melanoma incidence (odds ratio (OR), 4.9; 95% CI; 2.3-10.2) but also a correlation with Breslow thickness, suggesting that the polymorphism might play a role as a prognostic marker. However, conflicting findings have challenged this hypothesis so far. (McCarron et al., 2003; Amend et al., 2004; James et al., 2004; Randerson-Moor et al., 2004) , except for one study confirming a marginal association of the G/G genotype with Breslow thickness (McCarron et al., 2003) .
As the proposed effect of the EGF polymorphism on disease progression has been evaluated by assessing Breslow thickness but not survival, we hypothesized that the tumor promoting effect of the EGF 61*G allele might become more evident when disease severity is assessed during follow up after excision of the primary tumor. We thus examined the functional relevance and predictive value of the EGF A61G variant in the clinical course of MM patients by investigating the association of this SNP with disease free and melanoma specific over all survival.
RESULTS
Genotype frequencies of the EGF 5 0 untranslated region variant A61G
The overall genotype frequencies of the EGF A61G variant within the study group did not differ significantly from those previously reported in other Caucasian control populations (Shahbazi et al., 2002; McCarron et al., 2003; James et al., 2004; Randerson-Moor et al., 2004) : 45 (34.6%) of the patients were A/A, 65 (50%) were heterozygous A/G, and 20 (15.4%) were homozygous for the G/G genotype (Table 1) . Therefore, in accordance with the majority of previously reported data (McCarron et al., 2003; James et al., 2004; Randerson-Moor et al., 2004) our findings did not support the hypothesis that the EGF A61G promoter polymorphism was a potential risk factor for acquiring incident MM in our study population. Clinical and patient characteristics are presented in Table 2 .
Association of the EGF genotype with Breslow thickness and disease-free period With regard to Breslow thickness, we detected a trend for the G/G homozygous individuals to have thinner MM (2.8 mm (71.5) compared to 3.4 mm (71.9) in A/G, and 3.4 mm (71.9) in A/A individuals), although this finding was not statistically significant (Table 2) . We then assessed the potential role of the EGF polymorphism as a prognostic factor for disease-free period in a multivariate cox regression model adjusted for sex, age, and Breslow thickness as covariates. Of the 130 patients, 69 (53%) progressed from stage II to III (regional lymph node metastasis) within the observation period (mean 59 months 747). Twenty four patients without any signs of relapse were lost to follow-up, whereas nine patients died of other causes than MM. In addition to tumor thickness, which represented the strongest prognostic factor for outcome, the EGF 61 G/G genotype represented a significant risk factor for shorter disease-free period with a hazard ratio of 2.246 (95% CI: 1.06-4.78, P ¼ 0.036, Table 3 ) compared with A/A carriers, whereas the heterozygous EGF 61 A/G genotype appeared to have an intermediate risk for metastasis (hazard ratio: 1.541 (95% CI: 0.87-2.70), P ¼ 0.13, Table 3a, Figure 1a ).
Association of EGF genotype with MM-specific survival
Within the observation period (mean 10.1. years 74.4 years) a total of 48 patients died, of whom nine had to be censored due to death of other causes than melanoma. In parallel with disease-free survival, the G/G and the A/G genotype was significantly associated with shorter melanoma-specific survival. Compared to EGF A/A carriers, individuals with the homozygous EGF G/G genotype had a hazard ratio of 3.8 (95% CI: 1.5-9.5, P ¼ 0.004) of dying due to melanoma, whereas heterozygous EGF G/A individuals showed again an Figure 1b ).
DISCUSSION
We describe here for the first time a significant association between the high-expression homozygous G/G genotype of the EGF gene and shorter disease-free period and MMspecific survival compared to A/G and A/A carriers. This finding confirms the prognostic value of the EGF A61G SNP in MM which was originally proposed by Shahbazi et al.
Moreover, the G/G genotype had the highest risk for metastasis with 60% (12/20) becoming metastatic compared to 58% in A/G and 42% in A/A individuals (Table 2) , although this observation was not statistically significant.
With regards to Breslow thickness, we did not find a notable association between the EGF A61G variants and tumor thickness, which is in agreement with the majority of previously published reports (Amend et al., 2004; James et al., 2004; Randerson-Moor et al., 2004) . This finding of null association of the EGF A61G SNP and Breslow thickness together with the observed shorter diseasefree survival in G/G individuals appears paradoxical at first. If EGF contributes to disease progression in MM, an association with both Breslow thickness as well as disease-free survival would be expected. Several molecular studies have shown that the expression of the receptor for EGF, which is a membrane bound receptor tyrosine kinase, is higher in advanced stages of MM than it is in early lesions (Huang et al., 1996; Udart et al., 2001) . As the expression of the EGF receptor is higher in melanoma metastasis compared with primary MM (Udart et al., 2001) , it seems plausible that the stimulatory effect of EGF on melanoma cells become more evident in more advanced stages. Another explanation for the apparent paradox may be that there is a difference between an oncogenic mutation which is characteristic of the tumor and a polymorphism, which is a genomic variant present in both the tumor and the host. Oncogenic mutations provide the basis for the pathological character and clonal evolution of a tumor. Both, the higher expression of the EGF receptor in advanced stages and the low penetrance of the genetic variant might explain the long term but clinically relevant effects during disease progression. Tumor thickness might thus not be relevant for assessing the tumor-promoting effect of the EGF A61G SNP. However, the reason for this null association with Breslow thickness but positive correlation to disease-free survival still remains to be further elucidated.
MM is known to spread early into the surrounding tissue and invade both lymphatic and blood vessels (Garbe et al., Hazard ratios for continuous variables are calculated as increase in risk per mm of Breslow thickness and age in years, respectively, against the reference category (EGF 61 A/A). If A/G is taken as reference, the hazard ratio for G/G is 2.5 (95% CI: 1.1-5.5, P=0.026). 2003; Moehrle et al., 2004; Thomas et al., 2004) . To date, Breslow thickness is the most significant prognostic factor in MM at the time of diagnosis (Balch et al., 2001) . Our data suggest that the EGF A61G SNP might not only be capable of predicting the risk for early metastasis of MM but also disease-specific survival, which confirms the clinical relevance of the molecular biological findings, emphasizing the role of the mitogen-activated protein kinase pathway via RAS and BRAF in MM in vitro. However, our study clearly requires validation in a much larger study group.
MATERIALS AND METHODS

Patients
One hundred and thirty patients (70 male, 60 female; mean age: 56.1 years (714.6 years)) diagnosed with cutaneous MM with a Breslow thickness of more than 1.5 mm between January 1988 and December 1995, for whom formalin-fixed tissue for DNA preparation was available, were included in our study. All patients were diagnosed by two independent histopathologists at the Department of Dermatology, Medical University of Vienna. Patient characteristics are shown in Table 1 . Clinical data (including sex, age, and Breslow thickness) were retrieved from patients' records. The overall observation period did not differ significantly between all genotypes (mean 59 months 747). Disease-free period was determined as the time between removal of the primary tumor and signs of relapse as detected and confirmed by either sonography, computed tomography, or histopathology after surgical removal according to recent classifications (Garbe et al., 2003) . Melanoma-specific survival was assessed via record linkage with the Austrian Death registry, resulting in date of death (if occurred between January 1990 and December 2004) and cause of death encoded either according to the International Code of diseases Version 9 (ICD9) before 2002, later on according to the ICD 10. Before 1990, all patients were regularly seen in our outpatients unit for follow-up examinations. Death due to MM was considered present if the cause of death was either encoded as 1720-1729 (ICD 9) or C43.0-C43.9 (ICD 10), respectively. The Austrian death registry comprises all deaths within Austria and the deaths of Austrian residents in foreign countries. According to Austrian law all deaths have to undergo post mortem, if the final cause of death is not evident from the patients' history resulting in an overall post mortem frequency of 72% in our study. Thus, we estimate that diagnoses are correct in 95% of all cases. For statistical analysis only anonymized data were used containing no personal information except age in years and sex. The study was approved by the local ethics committee.
DNA extraction and analysis of the EGF 5 0 untranslated region variant A61G
Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue blocks as previously described (Ye et al., 2001; McCarron et al., 2003) . Briefly, two to four 20-mm sections were cut from each tissue block and were dewaxed in xylene (Sigma-Aldrich Corp., St Louis, MO) and xylene-ethanol washes. DNA was extracted from the resulting cellular material by proteinase-K digestion. Genotyping of the EGF (A/G) SNP 61 bp downstream of the major transcription start position was performed using a commercially available assay for allelic discrimination based on the principles of real-time PCR on a Taq Man Thermocycler (Applied Biosystems, Foster City, CA), as described elsewhere (McCarron et al., 2003) . Two independent researchers who were blinded to the clinical variables carried out interpretation and documentation of the results.
Statistical analysis
For statistical analyses the SPSS 10.0. software package (SPSS Inc., Chicago, IL) was used. Continuous data are presented as mean and standard deviation unless otherwise stated. Discrete data are given as counts and percentages. Univariate analysis was performed using an unpaired samples Student's t-test and w 2 tests as appropriate. Variables that were not normally distributed were log transformed before applying the t-test or analysis of variance as required. The influence of the EGF genotype on the main outcome variable, disease-free period, was assessed in the Cox proportional-hazards regression model adjusting for sex, age, and Breslow thickness. The assumptions underlying the proportional-hazards model (proportional hazards, lack of interaction, and linearity of continuous variables) were tested and found valid unless otherwise indicated. A two-sided P-value o0.05 was considered statistically significant.
